Duvortuxizumab - MacroGenics

Drug Profile

Duvortuxizumab - MacroGenics

Alternative Names: Anti-CD3/CD19 monoclonal-antibody; CD3-CD19 DART protein; CD3xCD19 DART molecule; JNJ-64052781; MGD 011

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MacroGenics
  • Developer Janssen Biotech; MacroGenics
  • Class Bispecific antibodies
  • Mechanism of Action CD19 antigen modulators; CD3 antigen modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma

Most Recent Events

  • 31 Aug 2017 Discontinued - Phase-I for Haematological malignancies (Second-line therapy or greater) in France, Israel, Spain, Belgium (IV)
  • 31 Aug 2017 Janssen terminates a phase I trial in Haematological malignancies (Second-line therapy or greater) in USA, Spain, Israel, France, Belgium due to treatment-related neurotoxicity (IV) (NCT02454270) (EudraCT2015-000485-63)
  • 31 Aug 2017 Janssen Biotech terminates its licence for duvortuxizumab
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top